Is Sermorelin Legal in Washington State?

The Short Answer on Washington State Legality

Sermorelin is legal to prescribe, dispense, and possess in Washington State under established federal and state pharmacy frameworks. Washington has not enacted any statute singling out sermorelin for restriction beyond the rules that apply to any compounded prescription drug. The practical legal boundary is federal, not local: a licensed prescriber must issue a patient-specific prescription, and the compounding pharmacy must hold a valid 503A or 503B registration.

Sermorelin acetate is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH). The FDA originally approved it as Geref in 1997 for diagnosing and treating growth hormone deficiency (GHD) in children. Geref's manufacturer voluntarily withdrew the branded product from the U.S. Market in 2008 for commercial reasons, not for safety findings. That withdrawal opened the door for licensed compounding pharmacies to manufacture patient-specific preparations under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Why the Federal Framework Governs First

The U.S. Drug Enforcement Administration (DEA) classifies sermorelin as a non-controlled substance. It does not appear in any DEA Schedule I through V. The DEA maintains a full list of scheduled substances under 21 U.S.C. § 812, and sermorelin is absent from every schedule.

Because sermorelin is not controlled, possession by a patient holding a valid prescription carries no federal criminal exposure beyond ordinary prescription-drug rules. Washington's Uniform Controlled Substances Act (RCW 69.50) mirrors the federal schedules for most substances, and sermorelin does not appear there either.

FDA's Bulk Substances Framework and Sermorelin

The FDA regulates which active pharmaceutical ingredients (APIs) compounding pharmacies may use. Under 503A, pharmacies may compound from bulk substances that are either (a) components of FDA-approved drugs, (b) on the FDA's 503A bulks list (Category 1), or (c) not yet placed on Category 2 (the prohibited list). As of the FDA's most recent 503A bulk substances update, sermorelin remains on neither the prohibited Category 2 list nor the positively nominated Category 1 list, meaning licensed 503A pharmacies may continue to compound it for individual patients while the FDA completes its review process.

This is a point of genuine federal uncertainty: the FDA has not yet made a final determination on whether sermorelin will be permanently permitted or restricted under 503A. Patients and prescribers should monitor FDA bulk-substance updates annually.

Washington State Pharmacy Board Rules

Washington's Department of Health licenses pharmacies through the Pharmacy Quality Assurance Commission (PQAC). Any pharmacy dispensing a compounded sermorelin product to a Washington patient must hold a valid Washington state pharmacy license in addition to complying with federal 503A or 503B standards.

503A vs. 503B: What the Difference Means for Patients

503A pharmacies compound for individual patients based on a valid prescription. They operate under state pharmacy board oversight, may not manufacture in large commercial batches, and must comply with USP <797> sterile compounding standards. Most telehealth-based sermorelin prescriptions are filled through 503A pharmacies.

503B outsourcing facilities may produce larger batches without patient-specific prescriptions, but they must register with the FDA and undergo FDA inspections. The FDA maintains a searchable database of registered 503B outsourcing facilities. A Washington clinician ordering from a 503B facility must confirm the facility is registered and that the compounded sermorelin meets current good manufacturing practice (CGMP) standards.

USP <797> Sterile Compounding Standards

Because sermorelin is administered by subcutaneous injection, the compounding pharmacy must follow USP <797> sterile compounding guidelines. The revised USP <797> chapter, effective November 2023, tightens beyond-use dating and environmental monitoring requirements for sterile preparations. Patients should confirm their dispensing pharmacy has passed a recent USP <797> compliance review.

How Growth Hormone Secretagogues Work: The Clinical Basis

Sermorelin binds to GHRH receptors on pituitary somatotroph cells, triggering pulsatile release of endogenous growth hormone (GH). The mechanism preserves the hypothalamic-pituitary feedback axis rather than bypassing it, which is the primary pharmacodynamic difference between sermorelin and exogenous recombinant human growth hormone (rhGH).

Growth Hormone Decline With Age

GH secretion declines at roughly 14% per decade after age 30, a process sometimes called somatopause. A 2019 review in the Journal of Clinical Endocrinology and Metabolism confirmed that mean 24-hour GH secretion falls from approximately 0.5 mg/day in young adults to less than 0.2 mg/day by age 60. Sermorelin's appeal in age-management medicine stems directly from this documented decline.

IGF-1 as the Clinical Monitoring Marker

Growth hormone stimulates hepatic production of insulin-like growth factor 1 (IGF-1). Clinicians use serum IGF-1 as the primary surrogate for GH axis activity. The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults recommends titrating GH therapy to achieve IGF-1 levels in the mid-normal range for age and sex. Although that guideline addresses rhGH directly, the same IGF-1 titration logic applies to sermorelin because the downstream marker is identical.

A baseline IGF-1 drawn before starting sermorelin, repeated at 3 months, gives the prescriber objective data to adjust dosing. Most Washington clinicians working with compounded sermorelin target an IGF-1 between 150 and 300 ng/mL, adjusted for the patient's age-specific reference range.

Who Can Prescribe Sermorelin in Washington?

Any Washington-licensed physician (MD or DO), naturopathic physician (ND), nurse practitioner (ARNP), or physician assistant (PA-C) operating within their scope of practice may prescribe sermorelin. Washington's Medical Practice Act (RCW 18.71) and the Naturopathic Physician Practice Act (RCW 18.36A) both permit prescribing of non-controlled compounds for legitimate medical purposes.

Scope of Practice Considerations

Naturopathic physicians in Washington hold full prescription authority for non-controlled substances under RCW 18.36A.040, which was expanded in 2019. A naturopathic physician may therefore prescribe compounded sermorelin without a collaborating MD, provided they conduct an adequate medical evaluation. ARNPs practicing under full practice authority (granted in Washington since 2023 under SB 5229) may also prescribe sermorelin independently.

Telehealth Prescribing

Washington permits telehealth prescribing when the provider has established a valid patient-provider relationship. The Washington State Medical Commission requires that telehealth prescribing of any drug, including compounded peptides, include a documented history, a review of relevant labs, and informed consent. A prescriber who issues a sermorelin prescription after a five-minute questionnaire and no lab review would not meet this standard, creating liability for the provider and legal uncertainty for the patient.

The Federation of State Medical Boards' model policy on telemedicine, which Washington's commission references, states that "the standard of care does not change based on the technology used to deliver care." Patients sourcing sermorelin through a telehealth platform should confirm the platform orders baseline labs before prescribing.

How to Get Sermorelin Legally in Washington: Step by Step

Getting a lawful sermorelin prescription in Washington involves four distinct steps. Skipping any one of them puts the prescription's legal standing at risk.

Step 1: Medical Evaluation and Lab Work

A licensed Washington provider orders a fasting serum IGF-1, basic metabolic panel, complete blood count, and, for men over 40, a PSA. Some clinicians also order a GH stimulation test (arginine-GHRH protocol) to document axis status before treatment. The Endocrine Society's guideline notes that a single random GH level is unreliable and that provocative testing or IGF-1 measurement is necessary for a valid GHD diagnosis.

Step 2: Prescription Issued to a Licensed Compounding Pharmacy

The prescriber writes a patient-specific prescription specifying the drug name (sermorelin acetate), concentration (commonly 2 mg/mL or 5 mg/mL in bacteriostatic water), quantity, and directions. The prescription must go to a pharmacy holding both a Washington PQAC license and federal 503A registration. The prescriber should not send the prescription to an offshore pharmacy or any vendor that ships without a prescription; doing so violates federal law under 21 U.S.C. § 331.

Step 3: Pharmacy Dispenses Under USP <797>

The compounding pharmacy prepares the sterile injectable under USP <797> clean-room conditions, attaches a patient-specific label, and ships the product directly to the patient. Refrigerated shipping (2°C to 8°C) is standard; beyond-use dating on reconstituted vials is typically 30 days refrigerated under the revised USP <797> guidance.

Step 4: Patient Self-Administers and Returns for Monitoring

Most protocols use 200 mcg to 500 mcg subcutaneously at bedtime, five nights per week. The nocturnal timing aligns with the body's natural GH pulse. A follow-up IGF-1 at 12 weeks allows the prescriber to titrate the dose or confirm that the pituitary is responding. A small but well-designed crossover study (N=21) published in the Journal of Clinical Endocrinology and Metabolism found that sermorelin at 0.03 mg/kg/day subcutaneously significantly increased mean IGF-1 compared with placebo (P<0.05) over 6 months in adults with partial GHD.

Risks of Non-Prescription or Gray-Market Sermorelin

Purchasing sermorelin without a prescription, from a research-chemical vendor, or from an offshore source carries legal and health risks that are distinct from the properly compounded product.

Legal Exposure

Importing an unapproved drug for personal use is subject to FDA enforcement discretion under the FDA's Personal Importation Policy. That discretion is not a right; the FDA explicitly states it may refuse entry to any unapproved drug regardless of intended personal use. A Washington resident receiving sermorelin from an unlicensed overseas pharmacy could have the shipment seized.

Quality and Safety Concerns

Research-chemical suppliers sell sermorelin labeled "not for human use" to avoid regulatory oversight. Independent third-party testing by organizations that assess research-chemical peptide purity has found significant variation in actual peptide content, with some samples containing less than 70% of the labeled dose and others containing unidentified impurities. The FDA's 2023 guidance on difficult-to-compound drugs reinforces that sterile injectables carry the highest contamination risk of any compounded dosage form.

Sermorelin from an unverified source does not carry the USP <797> sterility, potency, and endotoxin testing that a licensed pharmacy is required to perform.

Comparing Sermorelin to Other GHRH-Axis Peptides

Several other GHRH analogs and growth hormone secretagogues (GHSs) are used in age-management medicine. Their legal status differs meaningfully from sermorelin's.

Ipamorelin and CJC-1295

Ipamorelin is a GH secretagogue receptor agonist (GHSR agonist), not a GHRH analog. CJC-1295 is a modified GHRH analog. Neither has ever been FDA-approved. The FDA placed both ipamorelin and CJC-1295 on its 503A Category 2 nominated list in 2023, meaning compounding pharmacies operating under 503A are prohibited from using them while they remain on that list. Sermorelin, by contrast, was the active ingredient in an FDA-approved product (Geref), giving it a meaningfully stronger regulatory footing.

Tesamorelin

Tesamorelin (Egrifta SV) is FDA-approved for HIV-associated lipodystrophy. Its approved labeling limits use to that indication. Compounding tesamorelin outside that indication is subject to the same 503A bulk-substance scrutiny as sermorelin.

MK-677 (Ibutamoren)

MK-677 is an orally active GHSR agonist. It is not FDA-approved, not on the 503A permitted list, and is frequently sold as a research chemical. Washington clinicians cannot lawfully prescribe it as a compounded drug under current rules.

Sermorelin and Anti-Doping Regulations

Washington does not impose a state-level athlete drug-testing program, but competitive athletes subject to USADA, WADA, or NCAA jurisdiction face different rules. WADA's 2024 Prohibited List classifies all peptide hormones and releasing factors, including GHRH analogs, as prohibited in-competition and out-of-competition under Section 2. A Washington athlete holding a valid sermorelin prescription would still test positive under WADA rules and could face sanctions. Therapeutic use exemptions (TUEs) for GHRH analogs are rarely granted.

What Washington Patients Should Ask Their Provider

Before accepting a sermorelin prescription, a Washington patient should ask four direct questions:

1. Is the prescribing provider licensed in Washington and practicing within their scope?
2. Does the pharmacy hold a current Washington PQAC license and federal 503A registration?
3. Has the pharmacy provided a certificate of analysis confirming potency, sterility, and endotoxin testing for this specific lot?
4. Will baseline and follow-up IGF-1 levels be ordered to confirm response?

The U.S. Pharmacopeia notes that patients have the right to request a certificate of analysis (CoA) for any compounded sterile preparation. A licensed pharmacy should supply one without hesitation.